• Tonix received a Paragraph IV notice from Dr. Reddy’s for a proposed generic version of TONMYA 2.8 mg.
• The filing sets up potential patent litigation tied to Orange Book-listed TONMYA patents.
• Tonix plans to enforce its TONMYA intellectual property rights, but gave no timeline for a lawsuit.
• A suit filed within 45 days could trigger an automatic FDA approval stay for up to 30 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-045603), on October 02, 2026, and is solely responsible for the information contained therein.